Fk 506 and autoimmune disease: Perspective and prospects

Autoimmunity

Volumn 12, Issue 4, 1992, Pages 303-313

  Thomson, A W ^a   Starzl, T E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Autoimmune disease; FK 506

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

ARTHRITIS; AUTOIMMUNITY; DRUG MECHANISM; DRUG MONITORING; DRUG STRUCTURE; DRUG THERAPY; DRUG TOXICITY; ENCEPHALOMYELITIS; GLOMERULONEPHRITIS; HASHIMOTO DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS; NEPHROTIC SYNDROME; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; REVIEW; SKIN DISEASE; T LYMPHOCYTE; UVEITIS;

ANIMAL; AUTOIMMUNE DISEASES; HUMAN; TACROLIMUS;

EID: 0026650670     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916939209148473     Document Type: Article

References (62)

1. FK 506, a novel immunosuppressant isolated from Streptomyces. I. Fermentation, isolation and physicochemical and biological characteristics
2. FK 506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK 506 in vitro
3. FK 506. How much potential
4. FK 506 for liver, kidney and pancreas transplantation
5. Preclinical evaluation of a new potent immunosuppressive agent rapamycin
6. Adverse effects associated with the use of FK 506
7. Early trials with FK 506 as primary treatment in liver transplantation
8. Kidney transplantation under FK 506 immunosuppression
9. Preliminary experience with FK 506 in thoracic transplantation
10. Proceedings of the first international congress on FK 506
11. FK 506: a potential breakthrough in immunosuppression
12. FK 506. A potential breakthrough in immunosuppression-clinical implications
13. FK 506: Profile of an important new immunosuppressant
14. FK 506: an immunosuppressant for the 1990′s
15. Discovery of FK 506, a novel immunosuppressant isolated from Streptomyces tsukubaensis
16. A receptor for the immunosuppressant FK 506 is a cis-trans peptidyl-prolyl isomerase
17. A cytosolic binding protein for the immunosuppressant FK 506 has peptid-yl-prolyl isomerase activity but is distinct from cyclophilin
18. The immunosuppressant FK 506 selectively inhibits expression of early T cell activation genes
19. Immunosuppressive effect of FK 506 on in vitro lymphocyte alloactivation: synergism with cyclosporin A
20. Novel immunosuppressive agent, FK 506. In vitro effects on the cloned T cell activation
21. Antigen presentation and HLA-DR expression by FK 506-treated human monocytes
22. FK 506, a potent novel inhibitor of the release of proinflammatory mediators from human FcRI+ cells
23. FK 506, rapamycin and cyclosporine A: effects on IL-4 and IL-10 mRNA levels in a T helper cell line
24. Chemistry and biology of the immunophilins and their immunosuppressive ligands
25. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK 506 complexes
26. Nuclear association of a T-cell transcription factor blocked by FK 506 and cyclosporin A
27. A highly sensitive method to assay FK 506 in plasma
28. Assay of FK 506 in plasma
29. Pharmacokinetics of FK 506: Preclinical and clinical studies
30. Pharmacokinetics of FK 506 following oral administration. A comparison of FK 506 and cyclosporine
31. Toxicologic evaluation of FK 506
32. Post-transplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression
33. Is cyclophilin involved in the nephrotoxic mechanism of action of cyclosporin A
34. Immunosuppressive activity of FK 506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal
35. The influence of FK 506 on the thymus: an immunophenotypic and structural analysis
36. * CD8 T cells
37. Effects of a new immunosuppressive agent FK 506, on the efferent limb of the immune responses
38. Effects of a new immunosuppressive agent, FK 506, on experimental autoimmune uveoretinitis in rats
39. Effects of FK 506, 15-deoxy-spergualin and cyclosporine on experimental autoimmune uveoretinitis in the rat
40. Antigen-specific suppressor cells induced by FK 506 in experimental autoimmune uveoretinitis in the rat
41. FR900506 (FK 506) and 15-deoxyspergualine (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis
42. FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4′ lymphocyte adhesion to retinal pigment epithelial cells in vitro; implications for therapy of uveoretinitis
43. FK 506 treatment of S-antigen induced uveitis in primates
44. Immunosuppressive effect of FK 506 on collagen-induced arthritis in rats
45. Inhibition by FK 506 of established lesions of collagen-induced arthritis in rats
46. Effects of FK 506 on collagen arthritis in mice
47. FK 506 prevents spontaneous diabetes in the BB rat
48. Preventive effect of a new immunosuppressant FK 506 on insulinitis and diabetes in non-obese diabetic mice
49. Effects of FK 506, a novel immunosuppressive drug on murine systemic lupus erythematosus
50. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK 506
51. FK 506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis
52. The effects of a new immunosuppressive agent, FK 506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis
53. Immunosuppressive effect of FK 506 on experimental allergic encephalomyelitis in rats
54. The ability of myelin basic protein-sensitized leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisone
55. FK 506-a new therapeutic agent for severe, recalcitrant psoriasis
56. FK 506-a new therapeutic agent for severe, recalcitrant psoriasis
57. Influence of FK 506 on T lymphocytes, Langerhans cells, and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study
58. Efficacy of FK 506 in the treatment of pyoderma gangrenosum
59. A multicentre clinical open trial of FK 506 in refractory uveitis, including Behcet's disease
60. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood
61. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome
62. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation